β3AR-Dependent Brain-Derived Neurotrophic Factor (BDNF) Generation Limits Chronic Postischemic Heart Failure

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2023 Mar 8

PMID 36884028

Authors

Alessandro Cannavo

Seungho Jun

Giuseppe Rengo

Federica Marzano

Jacopo Agrimi

Daniela Liccardo

Andrea Elia

Gizem Keceli

Giovanna G Altobelli

Lorenzo Marcucci

Aram Megighian

Erhe Gao

Ning Feng

Kai Kammers

Nicola Ferrara

Livio Finos

Walter J Koch

Nazareno Paolocci

Affiliations

Soon will be listed here.

Abstract

Background: Loss of brain-derived neurotrophic factor (BDNF)/TrkB (tropomyosin kinase receptor B) signaling accounts for brain and cardiac disorders. In neurons, β-adrenergic receptor stimulation enhances local BDNF expression. It is unclear if this occurs in a pathophysiological relevant manner in the heart, especially in the β-adrenergic receptor-desensitized postischemic myocardium. Nor is it fully understood whether and how TrkB agonists counter chronic postischemic left ventricle (LV) decompensation, a significant unmet clinical milestone.

Methods: We conducted in vitro studies using neonatal rat and adult murine cardiomyocytes, SH-SY5Y neuronal cells, and umbilical vein endothelial cells. We assessed myocardial ischemia (MI) impact in wild type, β3AR knockout, or myocyte-selective BDNF knockout (myoBDNF KO) mice in vivo (via coronary ligation [MI]) or in isolated hearts with global ischemia-reperfusion (I/R).

Results: In wild type hearts, BDNF levels rose early after MI (<24 hours), plummeting at 4 weeks when LV dysfunction, adrenergic denervation, and impaired angiogenesis ensued. The TrkB agonist, LM22A-4, countered all these adverse effects. Compared with wild type, isolated myoBDNF KO hearts displayed worse infarct size/LV dysfunction after I/R injury and modest benefits from LM22A-4. In vitro, LM22A-4 promoted neurite outgrowth and neovascularization, boosting myocyte function, effects reproduced by 7,8-dihydroxyflavone, a chemically unrelated TrkB agonist. Superfusing myocytes with the β3AR-agonist, BRL-37344, increased myocyte BDNF content, while β3AR signaling underscored BDNF generation/protection in post-MI hearts. Accordingly, the β1AR blocker, metoprolol, via upregulated β3ARs, improved chronic post-MI LV dysfunction, enriching the myocardium with BDNF. Last, BRL-37344-imparted benefits were nearly abolished in isolated I/R injured myoBDNF KO hearts.

Conclusions: BDNF loss underscores chronic postischemic heart failure. TrkB agonists can improve ischemic LV dysfunction via replenished myocardial BDNF content. Direct cardiac β3AR stimulation, or β-blockers (via upregulated β3AR), is another BDNF-based means to fend off chronic postischemic heart failure.

Citing Articles

Bge. Attenuates the Cognitive Decline of Aging Mice by Enhancing BDNF/TrkB Pathway.

Sheng R, Zhao M, Pu K, Zhou Y, Zeng L, Chen Y Food Sci Nutr. 2025; 13(3):e70010.

PMID: 40027296 PMC: 11868736. DOI: 10.1002/fsn3.70010.

BDNF-induced BDNF release: A virtuous loop for the cardioprotective effects of exercise in post-ischemic heart failure.

Maroofi A, Safari F, Abbasi A Int J Cardiol Heart Vasc. 2025; 56:101623.

PMID: 39927379 PMC: 11804723. DOI: 10.1016/j.ijcha.2025.101623.

The Role of Cardiac Troponin and Other Emerging Biomarkers Among Athletes and Beyond: Underlying Mechanisms, Differential Diagnosis, and Guide for Interpretation.

Celeski M, Segreti A, Crisci F, Cricco R, Piscione M, Di Gioia G Biomolecules. 2025; 14(12.

PMID: 39766337 PMC: 11727179. DOI: 10.3390/biom14121630.

Impact and Mechanisms of Action of BDNF on Neurological Disorders, Cancer, and Cardiovascular Diseases.

Lei M, Liu Q, Nie J, Huang R, Mei Y, Pan D CNS Neurosci Ther. 2024; 30(12):e70138.

PMID: 39648800 PMC: 11626086. DOI: 10.1111/cns.70138.

Reiterated male-to-female violence disrupts hippocampal estrogen receptor β expression, prompting anxiety-like behavior.

Agrimi J, Bernardele L, Sbaiti N, Brondi M, DAngelo D, Canato M iScience. 2024; 27(9):110585.

PMID: 39228787 PMC: 11369378. DOI: 10.1016/j.isci.2024.110585.

References

Keceli G, Majumdar A, Thorpe C, Jun S, Tocchetti C, Lee D . Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function. J Gen Physiol. 2019; 151(6):758-770. PMC: 6571998. DOI: 10.1085/jgp.201812208. View

Bahls M, Konemann S, Markus M, Wenzel K, Friedrich N, Nauck M . Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP. Sci Rep. 2019; 9(1):15421. PMC: 6817886. DOI: 10.1038/s41598-019-51776-8. View

Rengo G, Cannavo A, Liccardo D, Zincarelli C, de Lucia C, Pagano G . Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. Circ Heart Fail. 2013; 6(6):1259-67. DOI: 10.1161/CIRCHEARTFAILURE.113.000329. View

Balligand J . Cardiac salvage by tweaking with beta-3-adrenergic receptors. Cardiovasc Res. 2016; 111(2):128-33. DOI: 10.1093/cvr/cvw056. View

Hiltunen J, Laurikainen A, Vakeva A, Meri S, Saarma M . Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischaemia and reperfusion. J Pathol. 2001; 194(2):247-53. DOI: 10.1002/path.878. View

Johansson S, Rosengren A, Young K, Jennings E . Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017; 17(1):53. PMC: 5297173. DOI: 10.1186/s12872-017-0482-9. View

Trappanese D, Liu Y, McCormick R, Cannavo A, Nanayakkara G, Baskharoun M . Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy. Basic Res Cardiol. 2014; 110(1):456. PMC: 4770805. DOI: 10.1007/s00395-014-0456-3. View

Halade G, Ma Y, Ramirez T, Zhang J, Dai Q, Hensler J . Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2013; 305(12):H1830-42. PMC: 3882541. DOI: 10.1152/ajpheart.00224.2013. View

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R . Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115(8):2108-18. PMC: 1180541. DOI: 10.1172/JCI24682. View

10.

Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I . Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. Arterioscler Thromb Vasc Biol. 2012; 32(8):1902-9. DOI: 10.1161/ATVBAHA.112.248930. View

11.

Minichiello L . TrkB signalling pathways in LTP and learning. Nat Rev Neurosci. 2009; 10(12):850-60. DOI: 10.1038/nrn2738. View

12.

Allen J, Armaiz-Pena G, Nagaraja A, Sadaoui N, Ortiz T, Dood R . Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018; 78(12):3233-3242. PMC: 6004256. DOI: 10.1158/0008-5472.CAN-16-1701. View

13.

Wang J, Li M, Ma X, Bai K, Wang L, Yan Z . Autoantibodies against the β3-adrenoceptor protect from cardiac dysfunction in a rat model of pressure overload. PLoS One. 2013; 8(10):e78207. PMC: 3795652. DOI: 10.1371/journal.pone.0078207. View

14.

Katare R, Kakinuma Y, Arikawa M, Yamasaki F, Sato T . Chronic intermittent fasting improves the survival following large myocardial ischemia by activation of BDNF/VEGF/PI3K signaling pathway. J Mol Cell Cardiol. 2008; 46(3):405-12. DOI: 10.1016/j.yjmcc.2008.10.027. View

15.

Walsh J, Tschakovsky M . Exercise and circulating BDNF: Mechanisms of release and implications for the design of exercise interventions. Appl Physiol Nutr Metab. 2018; 43(11):1095-1104. DOI: 10.1139/apnm-2018-0192. View

16.

Cannavo A, Rengo G, Liccardo D, Pun A, Gao E, George A . β-Blockade Prevents Post-Ischemic Myocardial Decompensation Via βAR-Dependent Protective Sphingosine-1 Phosphate Signaling. J Am Coll Cardiol. 2017; 70(2):182-192. PMC: 5527977. DOI: 10.1016/j.jacc.2017.05.020. View

17.

Zhang Z, Ding L, Jin Z, Gao G, Li H, Zhang L . Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling. PLoS One. 2014; 9(5):e98179. PMC: 4029889. DOI: 10.1371/journal.pone.0098179. View

18.

Michel L, Farah C, Balligand J . The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues. Cells. 2020; 9(12). PMC: 7761574. DOI: 10.3390/cells9122584. View

19.

Cannavo A, Liccardo D, Lymperopoulos A, Santangelo M, Femminella G, Leosco D . GRK2 Regulates α-Adrenergic Receptor-Dependent Catecholamine Release in Human Adrenal Chromaffin Cells. J Am Coll Cardiol. 2017; 69(11):1515-1517. PMC: 6645914. DOI: 10.1016/j.jacc.2017.01.016. View

20.

Fulgenzi G, Tomassoni-Ardori F, Babini L, Becker J, Barrick C, Puverel S . BDNF modulates heart contraction force and long-term homeostasis through truncated TrkB.T1 receptor activation. J Cell Biol. 2015; 210(6):1003-12. PMC: 4576863. DOI: 10.1083/jcb.201502100. View